Immune Biomarkers Show Promise in Guiding TNBC Treatment Decisions
High levels of tumor-infiltrating lymphocytes (TILs) strongly correlate with improved survival in triple-negative breast cancer patients, with 94% 5-year survival rates observed in patients with TIL levels ≥50%.
Nivolumab Plus Ipilimumab Shows Durable Survival Benefit in Advanced RCC
Eight-year data from CheckMate 214 show nivolumab plus ipilimumab demonstrates long-term efficacy in intermediate- and poor-risk advanced renal cell carcinoma (RCC).
Experts Highlight Critical Treatment Gaps in Metastatic Colorectal Cancer Management
Despite FDA approval of cetuximab plus encorafenib for BRAF V600E-mutated mCRC, significant challenges remain in treating patients who progress after BRAF inhibitor therapy.